Dr. Siegall is the founder of Seattle Genetics. He started the company in the year 1998.Siegall is the organizations chairman of board director, the head and the chief executive officer. Under his management Seattle Genetics has created different channels of antibody. Based cancer treatment ADCETRIS is one of those given acceleration permit by the United States. Clay is a trained scientist and Seattle Genetics was founded based on scientific creativity and the will to help patients. Siegall has been a good leader because he has managed the company all through. The company has recently developed an antibody drug called ADCS which is for treating cancer.
Siegall is a PhD holder. Before he joined Seattle Genetics he was working with the Bristol-Myers Squibb Pharmaceutical research institute between the year 1991 and 1997.Clay have also worked at National Cancer Centre. He joined Ultragenyx as an associate of board in 2014.He has been able to move this organization into some planned licenses specifically for technology like AbbVie, Pfizer, Roche and GlaxoSmithKline. Clay decided to separate activities that raised money which get millions of dollars through private and public financing. For example IPO which stand for Initial Public Offer. Initial Public Offer was conducted in the year 2001.
In a recent interview seagall stated that he is very proud that ADC has been used to treat over 1500 lymphoma patients worldwide up to date. He believes that ADCETRIS has the chance to be the base of treatment for CD30conveying malignancies. Beyond ADCETRIS, Clay states that they are developing seven stage forums. The company’s first ADC programs is the SGN-CD33A in severe myeloid and SGN-CD19A found in non-Hodgkin lymphoma. The program has transmitted encouraging information that has resulted to big clinical programs.
Clay said that the company has made important investments in their commodity channel and he is very excited about the company’s leading channel programs. The programs are the SGN-CD19A and SGN-CD33A.SGN-CD33A is the latest ADC that the company has developed to target CD33 .It is expressed on most severe myeloid leukemia cells despite the type.SGN-CD19A is an ADC that target CD19.It is a protein that is expressed broadly on B-cell malignancies.